Showing results (141-150 of 162) with videos related to

Sort By:
Pageof 17
Neurology (E-Cronicon)|September 29, 2025
Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical TargetingKenneth Blum, Kavya Mohankumar, Debasis Bagchi, et al.
JAMA Oncology|September 23, 2016
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh ScoreAndrew X Zhu, Ari David Baron, Peter Malfertheiner, et al.
NEJM Evidence|May 27, 2025
Randomized Trial of Lung and Diaphragm Protective Ventilation in ChildrenRobinder G Khemani, Anoopindar Bhalla, Justin C Hotz, et al.
Gene & Protein in Disease|August 1, 2025
Exploring dopamine as the master regulator of brain circuitry and mental health genomeKenneth Blum, Eric R Braverman, Alireza Sharafshah, et al.
Neurology (E-Cronicon)|March 16, 2026
Neurogenetics and Epigenetics of Spirituality and Religion: Seeking Genospirituality Via the Lens of Hierarchical Neuro-Spiritual Model (HNSM)Kai-Uwe Lewandrowski, Kenneth Blum, Morgan P Lorio, et al.
Psychology Research and Behavior Management|December 5, 2023
Neurogenetics and Epigenetics of LonelinessAbdalla Bowirrat, Igor Elman, Catherine A Dennen, et al.
Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.
Frontiers in Public Health|December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergiaKai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.
Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Pageof 17